Treatment of Post-poliomyelitis Syndrome by Intravenous Immunoglobulin
NCT ID: NCT04004390
Last Updated: 2020-03-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
17 participants
OBSERVATIONAL
2019-06-28
2019-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Randomized Study of Plasmapheresis or Human Immunoglobulin Infusion in Childhood Guillain-Barre Syndrome
NCT00004833
Post-Poliosyndrome Treated With Intravenous Immunoglobulin (IvIg)
NCT00231439
Intravenousimmunoglobulin (IVIg) for the Treatment of Inflammatory Myopathies
NCT00001261
Mini-pool Intravenous Immunoglobulin (MP-IVIG) in Guillain-Barré Syndrome
NCT04550611
Efficacy and Safety of Xepol (Human Immunoglobulin) in Subjects With Post-Polio Syndrome (PPS)
NCT00160082
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Collection of data retrospectively.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Pre- and post-therapeutic evaluation carried out
* Data transcribed in the computerized patient file
Exclusion Criteria
30 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Montpellier
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
MOIZIARD Vincent, intern
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Montpellier
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Uh Montpellier
Montpellier, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RECHMPL19_0322
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.